Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a systematic review

Abstract

Background Acute bronchiolitis caused by respiratory syncytial virus (RSV) has been associated with greater risk of recurrent wheezing and asthma. However, it is unclear whether this association is causal. RSV-specific monoclonal antibodies have been shown to reduce RSV-related hospitalisations in high-risk infants, but the longer-term follow-up has given conflicting evidence for prevention of recurrent wheeze or asthma. Objective We performed a systematic review and meta-analysis to determine whether monoclonal antibody prophylaxis against RSV bronchiolitis reduces the risk of subsequent recurrent wheeze or asthma. If so, this may support the hypothesis of causality. Methods Studies were identified via an online database search using Embase, MEDLINE, PubMed, Web of Science and the Cochrane Library. Manufacturers of monoclonal antibodies were contacted directly for unpublished data. The intervention of interest was RSV monoclonal antibody prophylaxis, and the primary outcome measure was recurrent wheeze and/or asthma. Studies were screened according to inclusion/exclusion criteria. Included studies were evaluated for quality and assessed for bias independently by 3 reviewers using the ‘Grading of Recommendations Assessment, Development and Evaluation’ (GRADE) approach. Results were extracted into 2 × 2 outcome tables and a meta-analysis carried out producing forest plots based on relative risk. Heterogeneity was assessed using the I2 statistic. Results The search identified 141 articles, which, after screening, resulted in eight studies (2 randomised controlled trials), thus including 11,195 infants in the meta-analysis. The overall result demonstrated a non-statistically significant reduction in relative risk of developing recurrent wheeze or asthma (RR 0.60; 95% CI 0.31 to 1.16). Study quality was generally low with evidence of publication bias and statistical heterogeneity. However, sub-group analysis excluding studies deemed to be ‘very low’ quality showed a relative risk of 0.42 (95% CI 0.22 to 0.80, p = 0.008). A further sub-group analysis for infants aged 32 to < 36 weeks showed a statistically significant relative risk of 0.35 (95% CI 0.14 to 0.86, p = 0.02). Discussion We did not identify an overall statistically significant benefit. However, our two sub-group analyses did find statistically significant benefits of monoclonal antibody therapy on the risk of recurrent wheeze and asthma. The main limitation of this study is the lack of high-quality randomised controlled trials, highlighting the need for more research in this field.

Association between bronchopulmonary dysplasia and early respiratory morbidity in children with respiratory distress syndrome: a case–control study using nationwide data

“…However, asthma development in BPD patients can result from LRI-related hospitalizations and their severity during the first 2 years of life. Previous studies have shown asthma is closely related to early life respiratory syncytial virus infection, and viral prophylaxis reduced childhood asthma prevalence 23 – 25 .…”

What is the Role of Vitamin D in the Severity and Control of Asthma in Children and Adolescents: a Protocol for a Systematic Review

“…Asthma is the most prevalent chronic respiratory disease worldwide [12]. If this review shows that vitamin D can help to control the disease, reducing the risk of severe asthma, it will support the hypothesis of a causal relationship between the level of that hormone and the development of asthma.…”

“…Furthermore, we hope that this study can support the premise about the biological mechanism by which this might occur. This can have potentially enormous clinical implications, especially with the possibility to reduce asthma attacks, corticosteroids use, and hospitalization crises [12].…”

Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?

“…Two recent systematic reviews have examined whether RSV prophylaxis can reduce the risk of wheezing in childhood. One, by our group [ 24 ], included eight studies (two of which were RCTs) of 11 195 infants. A pooled analysis across these studies demonstrated that a reduction in the relative risk of developing recurrent wheeze or asthma was not statistically significant (RR 0.60, 95% CI 0.31–1.16).…”